Lumida
/ATYR
⌘K
aTyr Pharma Inc

aTyr Pharma Inc

ATYR
$0.53USD+5.68%+0.03 today

MARKET CAP

52.0M

P/E (TTM)

FWD P/E

DAY RANGE

$0 – $1

52W RANGE

$0
$7

AI Summary

Stalk
Buy NowMedium

ATYR is forming an early Stage 1 consolidation near multi-year lows with valuations at the lower bound, and mean reversion is permitted. The 9/21 EMAs have flattened and now support price on shallow pullbacks, with no exhaustion signals visible. Price is holding in the lower half of the base, offering a favorable entry around the EMA cluster within the consolidation band. Under a speculative strategy, buying these pullbacks now aligns with upside breakout potential.

  • efzofitimod for pulmonary sarcoidosis addresses key ILD market
  • 60% workforce reduction yields $13M annual savings, runway to late 2028
  • Q2 EPS -$0.11 and negative earnings yield underscore profitability woes
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024FY 2025TREND
Sales, Adj.$235,000$190,000
YoY %-19.1%
P / Sales1143.9x383.2x
EV / Sales1211.8x462.0x
Gross Profit, Adj.$235,000$190,000
YoY %-19.1%
Margin %100.0%100.0%
EV / Gross Profit1211.8x462.0x
EBITDA, Adj.$-67.2M$-77.0M
YoY %-14.5%
Margin %-28598.3%-40506.8%
EV / EBITDA-4.2x-1.1x
EBIT$-67.9M$-77.6M
YoY %-14.3%
Margin %-28899.6%-40856.3%
EV / EBIT-4.2x-1.1x
Net Income$-64.0M$-74.1M
YoY %-15.8%
Net Margin-27243.8%-39009.5%
EPS (GAAP)-$0.86-$0.80
YoY %+7.0%